Rift GLP-1 Telehealth Program

Product Details

What Is Rift?

Rift is a telehealth platform for adults seeking professional evaluation for medical weight-management treatment. Its online process connects eligible patients with independent, state-licensed healthcare providers who determine whether a prescription is medically appropriate.

The weight-management program currently includes compounded semaglutide and compounded tirzepatide injections. These are prescription medications rather than dietary supplements. Treatment is provided only after medical review, and the final medication, formulation and dose are selected by the prescribing provider.

Who May Consider the Rift Program?

Adults interested in medical weight-management support may consider completing Rift’s online assessment. The official website generally presents GLP-1 treatment for adults with obesity or overweight, including people with a body mass index above 27 who may have additional weight-related concerns.

Completing the questionnaire does not guarantee approval or a prescription. People with unexplained weight changes, an eating disorder, severe digestive symptoms, pregnancy or significant medical conditions require an individualized clinical assessment before using any weight-management medication.

How Does Rift Work?

1. Complete the Online Assessment

The process begins with a secure health questionnaire covering medical history, current medications, weight-management goals and other information needed by the healthcare provider.

2. Receive a Provider Review

An independent licensed provider reviews the submitted information, generally within 24 to 48 hours. The provider may request additional details before deciding whether treatment is appropriate.

3. Obtain a Personalized Prescription

When approved, the provider selects a medication, formulation and dose based on the patient’s health profile. Treatment may involve compounded semaglutide or compounded tirzepatide.

4. Receive the Medication

The prescription is sent to a participating US compounding pharmacy. Medication is then shipped directly to the patient with the necessary treatment supplies.

5. Continue Medical Follow-Up

The program provides ongoing support and provider messaging. Patients should report side effects, health changes, new medications or concerns about dosing before making treatment changes.

Rift Treatment Options

Compounded Semaglutide

Compounded semaglutide is a once-weekly injectable GLP-1 receptor agonist formulation. GLP-1 activity may reduce appetite, increase feelings of fullness and slow stomach emptying.

The provider determines the starting dose and any later adjustments. Patients should not change the dose or injection volume without clear instructions from the prescribing provider.

Compounded Tirzepatide with Vitamin B6

Compounded tirzepatide acts on GLP-1 and GIP receptors and is administered as a weekly subcutaneous injection. Some Rift pharmacy options combine the compounded medication with vitamin B6.

The specific formulation depends on provider approval, state availability and the fulfilling pharmacy. The dose is normally increased gradually according to tolerance and the provider’s treatment plan.

Important Compounded Medication Information

Compounded medication should not be described as a generic or identical version of an FDA-approved GLP-1 medicine. Patients should confirm the pharmacy name, formulation, concentration, dose and injection instructions included with each shipment.

How May GLP-1 Treatment Support Weight Management?

GLP-1 receptor activity can influence appetite, satiety, digestion and glucose-dependent insulin release. Tirzepatide also acts on GIP receptors, adding a second metabolic signalling pathway.

These mechanisms may support reduced food intake and weight management when treatment is combined with appropriate nutrition, physical activity and medical follow-up. The outcome depends on the prescribed medication, dose, adherence, health history and individual response.

What the Program Includes?

• Secure online health assessment
• Review by an independent licensed provider
• Prescription when medically approved
• Compounded medication from a participating pharmacy
• Four weekly injections for a typical monthly program
• Injection supplies provided with the prescription
• Ongoing provider and care-team support
• Dose adjustments when clinically appropriate
• Free expedited medication shipping
• No additional charge based solely on a higher prescribed dose

Program contents may vary by medication, pharmacy, treatment term and state availability.

How to Use the Medication?

• Use the injection once weekly on the day selected with the provider.
• Follow the exact dose and volume printed on the pharmacy instructions.
• Inject under the skin only in an approved area, such as the abdomen, thigh or upper arm.
• Rotate injection locations rather than repeatedly using the same spot.
• Use a new sterile needle and syringe for every injection.
• Store the medication according to the pharmacy instructions.
• Do not double the next dose after a missed injection unless the provider directs it.
• Contact the care team before changing the medication, concentration or dose.

Compounded injectable concentrations can differ between pharmacies. Patients should measure doses using the units shown on their own prescription rather than instructions written for another medication or person.

Warnings and Precautions

• Do not use prescription GLP-1 medication without provider approval.
• Inform the provider if you are pregnant, breastfeeding or planning pregnancy.
• Discuss any personal or family history of medullary thyroid carcinoma.
• Report a history of multiple endocrine neoplasia syndrome type 2.
• Inform the provider about pancreatitis, gallbladder disease or severe digestive problems.
• Discuss kidney disease, dehydration risk and recurring vomiting or diarrhea.
• List all insulin, diabetes medicines and glucose-lowering products.
• Report a history of diabetic retinopathy or significant vision changes.
• Tell the provider about planned surgery or procedures requiring anesthesia.
• Do not combine the treatment with another semaglutide, tirzepatide or GLP-1 product unless specifically directed.
• Seek urgent care for severe abdominal pain, serious allergic symptoms or signs of dehydration.

Tirzepatide carries a boxed warning concerning thyroid C-cell tumors observed in animal studies. It is unknown whether this risk occurs in humans, making personal and family thyroid history important during assessment.

Possible Side Effects and Interactions

Common GLP-1-related effects include nausea, diarrhea, constipation, vomiting, reduced appetite, abdominal discomfort and indigestion. Symptoms may be more noticeable when treatment begins or after the dose increases.

More serious concerns can include pancreatitis, gallbladder problems, kidney injury related to dehydration, severe allergic reactions and significant digestive complications. Using GLP-1 treatment with insulin or certain diabetes medicines may increase the risk of low blood sugar.

Because these medicines slow stomach emptying, they may affect the absorption or timing of some oral medications. Patients should provide the prescribing provider with a complete list of prescriptions, supplements and non-prescription products.

Important Limitations

• Treatment requires approval from a licensed healthcare provider.
• Eligibility and medication availability vary by state.
• Results from branded clinical trials cannot be guaranteed with compounded formulations.
• Weight-management outcomes vary between patients.
• Side effects may limit treatment or require dose changes.
• Medication does not replace balanced nutrition or physical activity.
• Long-term treatment and follow-up may be required to maintain progress.
• Insurance coverage is not presented as part of the standard cash-pay program.

Pharmacy and Quality Information

Pros

• Entire assessment process is completed online.
• Treatment requires independent licensed provider approval.
• Offers semaglutide and tirzepatide program options.
• Pricing includes medication and provider review.
• Higher prescribed doses do not carry separate surcharges.
• Free expedited medication shipping is included.
• Ongoing support and provider messaging are available.
• Monthly and multi-month program formats are offered.

Cons

• Treatment availability varies by state.
• GLP-1 medicines can cause significant side effects.
• Injectable dosing requires careful measurement and administration.
• Approval and medication choice are not guaranteed.
• Cash-pay treatment can create an ongoing expense.
• Outcomes vary and depend on continued lifestyle changes.
• Some programs may renew unless paused or cancelled.

Pricing

Current weight-management pricing includes provider review, prescribed medication, continuing support and shipping.

The $419 promotional option applies to the Nova Pharmacy quarterly tirzepatide-plus-B6 program and is advertised through July 31, 2026, at 11:59 p.m. ET.

Prices are flat across the prescribed dose levels offered within the selected program. Final availability depends on the patient’s state, provider decision, pharmacy assignment and chosen treatment term.

Pricing and availability were checked on July 24, 2026, and may change on the official website.

Cancellation and Refund Considerations

Prescription medication is prepared for an individual patient, which can limit cancellation or refund eligibility after the pharmacy begins processing the order. Patients should review the current renewal, cancellation and refund terms before submitting payment.

Any cancellation request should be made promptly through Rift support. Treatment should not be stopped or restarted solely because of billing changes without discussing medication safety and dosing with the prescribing provider.

Pharmacist Note

Confirm the medication name, concentration, prescribed dose and syringe units before every injection. Compounded concentrations may vary between pharmacies. Contact the provider or dispensing pharmacy whenever the written instructions and supplied syringe markings appear inconsistent.

FAQs

1.What type of service is Rift?

Rift is a telehealth technology platform that connects patients with independent licensed providers and participating US compounding pharmacies for prescription weight-management evaluation, treatment and continuing support.

2.Which weight-management medications are offered?

The current program includes compounded semaglutide and compounded tirzepatide injections. Medication selection, formulation and dosage depend on provider approval, state availability and the assigned pharmacy.

3.How often are the injections used?

Both treatment options are generally administered once weekly. The prescribing provider and pharmacy supply the exact injection schedule, concentration, volume and dose-escalation instructions for each patient.

4.Is a prescription required?

Yes. An independent licensed provider must review the patient’s health information and determine that treatment is medically appropriate before a prescription can be sent to a pharmacy.

5.What does the price include?

Program pricing generally includes the online provider review, prescribed compounded medication, required injection supplies, ongoing support and expedited shipping. The selected treatment term determines the final charge.

6.Are higher medication doses more expensive?

Rift advertises flat-rate program pricing without additional dose surcharges. Dose changes remain medical decisions and must be approved by the prescribing healthcare provider rather than selected by the patient.

7.Where is treatment available?

Availability depends on the patient’s state and the licensure and shipping coverage of participating providers and pharmacies. The provider makes the final treatment and pharmacy determination.

Medical Disclaimer

This information is for general educational purposes and does not replace medical diagnosis or treatment. Eligibility, medication selection, dose and monitoring must be determined by a qualified licensed healthcare provider.

Sources and Program Review Information

• Official Rift website and weight-management program information. (joinrift.com)
• Official Rift pricing and compounded treatment pages. (joinrift.com)
• Official Rift terms, contact and refund information. (joinrift.com)
• FDA information concerning compounded medications and compounded GLP-1 products. (U.S. Food and Drug Administration)
• MedlinePlus tirzepatide safety information. (MedlinePlus)
• Program and pricing information checked: July 24, 2026